Shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSIW – Get Free Report) shot up 15.2% on Thursday . The stock traded as high as $1.67 and last traded at $1.67. 225 shares were traded during trading, a decline of 95% from the average session volume of 4,498 shares. The stock had previously closed at $1.45.
TriSalus Life Sciences Stock Performance
The firm has a 50 day moving average of $1.20 and a two-hundred day moving average of $1.22.
TriSalus Life Sciences Company Profile
TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.
Featured Stories
- Five stocks we like better than TriSalus Life Sciences
- What Are Growth Stocks and Investing in Them
- Unity Stock: Is a True Turnaround Finally Taking Shape?
- What Are Trending Stocks? Trending Stocks Explained
- DuPont’s Electronics Spinoff: The Start of Something Big
- What is the Australian Securities Exchange (ASX)
- The Trade Desk Crashes on Earnings, But Growth Catalysts Persist
Receive News & Ratings for TriSalus Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TriSalus Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
